# Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

> **NCT07040943** · PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Refractory Malignant Solid Tumors
- mRNA Vaccine
- Interleukin

## Interventions

- **BIOLOGICAL:** IL-22BP

## Key facts

- **NCT ID:** NCT07040943
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-29
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07040943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07040943, "Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07040943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*